Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3501-3520 of 3,900 trials

Durvalumab for Non-Surgical Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of the immunotherapy durvalumab followed by radiation in patients with early stage or locally advanced non-small cell lung cancer. This trial aims to find out if this treatment approach can help those who cannot have surgery.

Non-Small Cell Lung Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Antibiotics in Children with Brain Tumors

We are studying how different antibiotics move into the cerebrospinal fluid of children with malignant brain tumors. This research may help improve treatment for infections in these patients.

Brain Tumors>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesOncologyPediatrics

Levosimendan for Faster Recovery from Ventilation

We are studying whether levosimendan can help critically ill patients wean off invasive ventilation more quickly. The trial also examines patient experiences and healthcare needs during recovery.

Difficulty Stopping Mechanical Ventilation≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyPulmonology

Breast Cancer: Inavolisib Treatment Study

We are testing a new treatment using Inavolisib for patients with early-stage, PIK3CA-mutated breast cancer. The study aims to evaluate how safe and effective this treatment is for participants.

Early-Stage Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Non-Small Cell Lung Cancer: Cemiplimab Treatment Study

We are investigating whether treatment decisions based on blood tests for tumor DNA improve outcomes for patients with advanced non-small cell lung cancer. This includes testing Cemiplimab alone or with chemotherapy.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Kidney Transplant: Mannitol vs. Normal Saline

We are studying whether mannitol can help improve kidney transplant outcomes by reducing delayed graft function and early rejections. This trial involves both kidney donors and recipients.

End-Stage Renal Disease>2 yearsMonitoring phase (IV)Standard MedicinesNephrologyUrology

Insulin Eye Drops for Persistent Corneal Epithelial Defects

We are studying whether insulin eye drops can help heal persistent corneal defects better than standard treatments. This trial will also assess the safety of insulin drops and explore factors that may influence treatment success.

Persistent Corneal Epithelial Defect1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Triple-Negative Breast Cancer: Dato-DXd Treatment

We are studying a new drug for patients with triple-negative breast cancer and brain metastases to see if it can help shrink tumors and improve survival. The trial also examines safety and quality of life for participants.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Blood Cancers: Sonrotoclax Safety Study

We are investigating new dosing schedules for Sonrotoclax in adults with blood cancers. The study aims to understand the safety and tolerability of this treatment approach.

Chronic Lymphocytic LeukemiaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Peyronie's Disease: FAPI-PET/CT and FDG-PET/CT Scans

We are investigating whether special imaging scans can detect inflammation and active tissue changes in men with acute Peyronie's Disease. This may help improve diagnosis and treatment options.

Peyronie's Disease6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementOtolaryngologyUrology

Dapansutrile Tablets for Acute Gout Flare

We are studying whether dapansutrile can reduce joint pain and other symptoms in people experiencing an acute gout flare. This trial compares the medication to a placebo to assess its effectiveness and safety.

Gout Flare≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

Kidney Protection: Cilastatin vs. Thiosulfate

We are comparing cilastatin and thiosulfate to see which better protects kidneys during surgery with chemotherapy for cancer patients. This study aims to reduce kidney damage after the procedure.

Acute Kidney Injury>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrologyOncology

Palmoplantar Pustulosis: Delgocitinib Cream Study

We are investigating whether delgocitinib cream can effectively treat adults with mild to severe palmoplantar pustulosis compared to a dummy cream. The study will also assess the safety and impact on quality of life.

Palmoplantar Pustulosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesDermatology

Multiple Sclerosis: Ozanimod Treatment Study

We are investigating how ozanimod affects inflammation in the brain and spinal cord for individuals with Multiple Sclerosis. This study aims to understand its potential benefits and any side effects.

Relapsing Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

V540C Vaccine Study in Healthy Adults

We are investigating the V540C vaccine to see how it works in healthy adults. This study aims to assess its safety and immune response.

Human Papilloma Virus Infection1-2 yearsSafety phase (I)Infectious DiseasesOncology

Cushing's Disease: Silycus® Treatment Study

We are studying the effects of Silycus® on lowering cortisol levels in patients with Cushing's disease. The trial will also evaluate how well patients tolerate the treatment and its impact on their symptoms.

Cushing's Disease1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinology

HIV Treatment: Venetoclax Study

We are testing the safety of a medication called venetoclax in people living with HIV who are on antiretroviral therapy. The aim is to see if it can help reduce the size of the HIV reservoir in the body.

HIV-1 Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious Diseases

Malaria Prevention: Atovaquone-Proguanil Study

We are testing a weekly dose of atovaquone-proguanil to see if it can prevent malaria in healthy volunteers. The study also looks at the safety of the medication and how it behaves in the body.

Malaria6-12 monthsEfficacy phase (II)16-20 visitsInvestigational MedicinesInfectious Diseases

Nintedanib for Nosebleeds in Hereditary Hemorrhagic Telangiectasia

We are studying whether nintedanib can help reduce the duration of nosebleeds in patients with hereditary hemorrhagic telangiectasia. The trial also examines its effects on quality of life and potential side effects.

Hereditary Hemorrhagic Telangiectasia1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHematologyInternal Medicine

Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis

We are studying a new treatment using neural stem cells for people with ALS. The trial aims to assess safety and whether it may help slow disease progression.

Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology